Revance Announces Two Publications Highlighting the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) For Injection in the Aesthetic Surgery Journal
Retrieved on:
Monday, September 19, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Adult, Headache, Safety, Rest, Aesthetic Surgery Journal, Publication, Week, Eyebrow, Population, Innovation, Medical Affairs Bureau, Therapy, OLS, Patient, FHL, Nasdaq, Doctor of Philosophy, PFWS, Overalls, SAKURA, Pharmaceutical industry, White
DAXXIFY demonstrated long-lasting efficacy in all subgroups, consistent with the overall population results of the SAKURA clinical trials.
Key Points:
- DAXXIFY demonstrated long-lasting efficacy in all subgroups, consistent with the overall population results of the SAKURA clinical trials.
- Efficacy and safety were analyzed by age (18-45, >45-55, and >55 years) and race (Asian, Black/African American, and White).
- DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study.
- A large, open-label, phase 3 safety study of daxibotulinumtoxinA for injection in glabellar lines: a focus on safety from the SAKURA 3 study.